Literature DB >> 35175188

Assessing quality of blood components derived from whole blood treated with riboflavin and ultraviolet light and separated with a fully automated device.

Michał Bubiński1, Agnieszka Gronowska1, Paweł Szykuła1, Agnieszka Woźniak1, Aleksandra Rodacka2, Scott Santi3, Marcia Cardoso4, Elżbieta Lachert5.   

Abstract

BACKGROUND: Combining pathogen reduction and automated separation of whole blood (WB), together with the use of improved additive solutions, may increase reproducibility and extend shelf-life of blood components.
MATERIALS AND METHODS: Forty WB units were collected from volunteer donors and randomised 1:1 into two groups: 1) pathogen reduction with riboflavin and ultraviolet light (PRT); or 2) no treatment (Control). After two hours (h) at room temperature, all units underwent fully automated separation into red blood cell concentrate (RBCC), plasma and leukopack components. RBCCs were leukoreduced and stored in phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) solution while plasma units were shock frozen within 8 h of collection and stored at ≤ -25°C. RBCCs were sampled on day 1 and weekly thereafter until day 42, while plasma was sampled on days 1 and 30. The main study objective was to assess the in vitro quality of separated RBCCs using biochemical and haematological parameters. Plasma protein content after one cycle of freeze-thaw was also analysed.
RESULTS: The quality of RBCCs was largely comparable between the PRT and Control groups, except for a significantly higher degree of haemolysis and extracellular potassium levels in the PRT group after 35 days of storage. While potassium concentration was significantly higher in the PRT group at all timepoints, the degree of haemolysis exceeded the accepted European threshold (i.e., <0.8% of red cell mass in ≥ 90.0% of tested units) after day 35. Most plasma protein levels were significantly lower in the PRT than the Control group at both day 1 and day 30. DISCUSSION: Pathogen reduction with riboflavin and ultraviolet light treatment of WB can be combined with fully automated separation to obtain RBCCs that may be stored for up to 35 days in PAGGSM solution with acceptable quality, comparable to that of RBCCs from untreated blood. The relative differences between factor concentrations in plasma from the PRT and the Control groups were similar during the 30-day storage.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35175188      PMCID: PMC9480972          DOI: 10.2450/2022.0278-21

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   5.752


  35 in total

1.  In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood.

Authors:  Jose A Cancelas; Neeta Rugg; Dana Fletcher; P Gayle Pratt; D Nicole Worsham; Susan K Dunn; Susanne Marschner; Heather L Reddy; Raymond P Goodrich
Journal:  Transfusion       Date:  2011-01-28       Impact factor: 3.157

Review 2.  The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.

Authors:  Raymond P Goodrich; Richard A Edrich; Junzhi Li; Jerard Seghatchian
Journal:  Transfus Apher Sci       Date:  2006-08-28       Impact factor: 1.764

3.  Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.

Authors:  Paolo Rebulla; Stefania Vaglio; Francesco Beccaria; Maurizio Bonfichi; Angelo Carella; Federico Chiurazzi; Serelina Coluzzi; Agostino Cortelezzi; Giorgio Gandini; Gabriella Girelli; Maria Graf; Paola Isernia; Giuseppe Marano; Maurizio Marconi; Rachele Montemezzi; Barbara Olivero; Marianna Rinaldi; Laura Salvaneschi; Nicola Scarpato; Paolo Strada; Silvano Milani; Giuliano Grazzini
Journal:  Transfusion       Date:  2017-02-24       Impact factor: 3.157

Review 4.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

5.  The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases.

Authors:  Pavel Trakhtman; Irina Kumukova; Nikolay Starostin; Daria Borsakova; Dmitry Balashov; Anastasia Ignatova; Leilya Kadaeva; Galina Novichkova; Alexander Rumiantcev
Journal:  Vox Sang       Date:  2019-02-19       Impact factor: 2.144

6.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

7.  Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies.

Authors:  Luis Larrea; María-Isabel Ortiz-de-Salazar; Patricia Martínez; Roberto Roig
Journal:  Transfus Apher Sci       Date:  2015-01-16       Impact factor: 1.764

8.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

Authors:  Jeffrey McCullough; David H Vesole; Richard J Benjamin; Sherrill J Slichter; Alvaro Pineda; Edward Snyder; Edward A Stadtmauer; Ileana Lopez-Plaza; Steven Coutre; Ronald G Strauss; Lawrence T Goodnough; Joy L Fridey; Thomas Raife; Ritchard Cable; Scott Murphy; Frank Howard; Kathryn Davis; Jin-Sying Lin; Peyton Metzel; Laurence Corash; Antonis Koutsoukos; Lily Lin; Donald H Buchholz; Maureen G Conlan
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

9.  Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.

Authors:  Heather F Pidcoke; Steve J McFaul; Anand K Ramasubramanian; Bijaya K Parida; Alex G Mora; Chriselda G Fedyk; Krystal K Valdez-Delgado; Robbie K Montgomery; Kristin M Reddoch; Armando C Rodriguez; James K Aden; John A Jones; Ron S Bryant; Michael R Scherer; Heather L Reddy; Raymond P Goodrich; Andrew P Cap
Journal:  Transfusion       Date:  2013-01       Impact factor: 3.157

10.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Authors:  Frédéric Garban; Audrey Guyard; Helene Labussière; Claude-Eric Bulabois; Tony Marchand; Christiane Mounier; Denis Caillot; Jacques-Olivier Bay; Valérie Coiteux; Aline Schmidt-Tanguy; Catherine Le Niger; Christine Robin; Patrick Ladaique; Simona Lapusan; Eric Deconinck; Carole Rolland; Alison M Foote; Anne François; Chantal Jacquot; René Tardivel; Pierre Tiberghien; Jean-Luc Bosson
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.